A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma

被引：0
|
作者：
Budde, L. Elizabeth
Martin, Daniel B.
Philip, Mary
Shustov, Andrei R.
Gooley, Theodore
Chen, Tara L.
Libby, Edward N.
Chen, Eric Y.
Kojouri, Kiarash
Langerak, Alan
Roden, Jennifer E.
Kammerer, Britt E.
Knudsen, Nancy L.
Smith, Stephen Douglas
Press, Oliver W.
Gopal, Ajay K.
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[4] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA
[5] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[6] Univ Washington, Sch Pharm, Seattle, WA 98195 USA
[7] Grp Hlth Permanente, Bellevue, WA USA
[8] Skagit Valley Hosp, Reg Canc Care Ctr, Mt Vernon, WA USA
[9] St Alphonsus Reg Med Ctr, Boise, ID USA
[10] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8533
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
    Nakamura, Nobuhiko
    Kasahara, Senji
    Kitagawa, Junichi
    Nakamura, Hiroshi
    Sawada, Michio
    Fukuno, Kenji
    Shibata, Yuhei
    Kaneda, Yuto
    Hara, Takeshi
    Kanemura, Nobuhiro
    Tsurumi, Hisashi
    Shimizu, Masahito
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [22] Phase I Study of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Chihara, Dai
    Oki, Yasuhiro
    Fayad, Luis
    Wesson, Emily
    Ruben, Charnelle
    Horowitz, Sandra B.
    Woolery, Joseph
    Feng, Lei
    Garg, Naveen
    Ahmed, Sairah
    Khouri, Issa F.
    Fanale, Michelle A.
    BLOOD, 2014, 124 (21)
  • [23] EFECTIVITY AND SAFETY OF BENDAMUSTINE-RITUXIMAB IN AGED PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA
    Canovas, A.
    Barreiro, G.
    Alonso, J. J.
    HAEMATOLOGICA, 2012, 97 : 670 - 670
  • [24] A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma
    Ikoma, Yoshikazu
    Nakamura, Nobuhiko
    Kitagawa, Junichi
    Miwa, Takao
    Takada, Eri
    Matsumoto, Takuro
    Shibata, Yuhei
    Nakamura, Hiroshi
    Kanemura, Nobuhiro
    Kasahara, Senji
    Hara, Takeshi
    Sawada, Michio
    Tsurumi, Hisashi
    Shimizu, Masahito
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
  • [25] Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
    Moskowitz, Alison J.
    Hamlin, Paul A., Jr.
    Perales, Miguel-Angel
    Gerecitano, John
    Horwitz, Steven M.
    Matasar, Matthew J.
    Noy, Ariela
    Palomba, Maria Lia
    Portlock, Carol S.
    Straus, David J.
    Graustein, Tricia
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 456 - 460
  • [26] Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma
    Tisi, Maria Chiara
    Paolini, Rossella
    Piazza, Francesco
    Ravelli, Erika
    Tecchio, Cristina
    Sartori, Roberto
    Famengo, Barbara
    D'Amore, Emanuele Stefano Giovanni
    Carli, Giuseppe
    Perbellini, Omar
    Di Bona, Eros
    Ruggeri, Marco
    Visco, Carlo
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (12) : E386 - E389
  • [27] a Phase I Trial of Bendamustine in Combination with Clofarabine and Etoposide in Pediatric Patients with Relapsed or Refractory Hematologic Malignancies
    Jeha, Sima
    Metzger, Monika L.
    Crews, Kristine R.
    Campbell, Patrick
    Ribeiro, Raul C.
    Cheng, Cheng
    Peyton, Melissa
    Panetta, Carl
    Yang, Jun
    Pui, Ching-Hon
    Bhojwani, Deepa
    BLOOD, 2016, 128 (22)
  • [28] Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
    Torka, Pallawi
    Groman, Adrienne
    Wong, Jerry
    Nichols, Jenna
    Kader, Angela
    Mavis, Cory
    Anampa-Guzman, Andrea
    Sait, Sheila Jani
    Block, AnneMarie
    Przespolewski, Eugene
    Mohr, Alice
    Lund, Ian
    McWhite, Kenneth
    Kostrewa, Jessica
    DeMarco, Joseph
    Johnson, Michael
    Darrall, Andrea
    Thomas, Roshneke
    Sundaram, Suchitra
    Ghione, Paola
    Hutson, Alan
    Hernandez-Ilizaliturri, Francisco J.
    BLOOD ADVANCES, 2023, 7 (07) : 1146 - 1155
  • [29] A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma
    Budde, Lihua E.
    Zhang, Michelle M.
    Shustov, Andrei R.
    Pagel, John M.
    Gooley, Ted A.
    Oliveira, George R.
    Chen, Tara L.
    Knudsen, Nancy L.
    Roden, Jennifer E.
    Kammerer, Britt E.
    Frayo, Shani L.
    Warr, Thomas A.
    Boyd, Thomas E.
    Press, Oliver W.
    Gopal, Ajay K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (02) : 183 - 191
  • [30] Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma - Interim Analysis of Phase II Clinical Trial
    Kedmi, Meirav
    Ribakovsy, Elena
    Benjamini, Ohad
    Schiby, Ginette
    Barshack, Iris
    Raskin, Stephen P.
    Eshet, Yael
    Mehr, Ramit
    Bitansky, Guy
    Nagler, Arnon
    Avigdor, Abraham
    BLOOD, 2018, 132
12345